R&D News | pharmaphorum

News

How effective data management can support NHS Trusts to hit their targets

Roche, Boehringer tap biosensor firms for patient studies

Roche and Boehringer Ingelheim have both formed partnerships with tech companies this week to develop and deploy wearable biosensor te

News

Merck's Keytruda flunks another prostate cancer test

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.

News

Pliant seeks $250m offering on lung fibrosis data

Buoyed by encouraging mid-stage clinical results for its idiopathic pulmonary fibrosis therapy bexotegrast, Pliant Therapeutics filed a $175million public offering, and then swiftly raised

News

Sanofi, CytoReason expand AI deal into IBD

Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver artificial intelligence (AI) for drug discovery and development in the fiel

News

Morphic loses second partner as J&J exits integrin alliance

Morphic Therapeutic has lost Johnson & Johnson's Janssen Pharma as a partner, following the termination of an alliance to develop drugs targeting integrins first agreed in 2019.

News

BeiGene's Brukinsa FDA approved for CLL/SLL

Beijing-based pharma, BeiGene’s

Roche, Boehringer tap biosensor firms for patient studies

Merck's Keytruda flunks another prostate cancer test

Pliant seeks $250m offering on lung fibrosis data

Sanofi, CytoReason expand AI deal into IBD

Morphic loses second partner as J&J exits integrin alliance

BeiGene's Brukinsa FDA approved for CLL/SLL

Parexel buys Vitrana to boost patient safety toolkit

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks